| Year |
Citation |
Score |
| 2022 |
So JY, Yang HH, Park WY, Skrypek N, Ishii H, Chen JM, Lee MP, Yang L. DNA methyltransferase 3B-mediated intra-tumoral heterogeneity and therapeutic targeting in breast cancer recurrence and metastasis. Molecular Cancer Research : McR. PMID 35857355 DOI: 10.1158/1541-7786.MCR-21-0887 |
0.365 |
|
| 2021 |
Stoup N, Liberelle M, Schulz C, Cavdarli S, Vasseur R, Magnez R, Lahdaoui F, Skrypek N, Peretti F, Frénois F, Thuru X, Melnyk P, Renault N, Jonckheere N, Lebègue N, et al. The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis. Cancers. 13. PMID 34830899 DOI: 10.3390/cancers13225746 |
0.721 |
|
| 2020 |
Vandamme N, Denecker G, Bruneel K, Blancke G, Akay Ö, Taminau J, De Coninck J, De Smedt E, Skrypek N, Van Loocke W, Wouters J, Nittner D, Köhler C, Darling DS, Cheng PF, et al. The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype. Cancer Research. PMID 32503808 DOI: 10.1158/0008-5472.Can-19-2373 |
0.352 |
|
| 2020 |
Yang L, So JY, Skrypek N, Yang HH, Merchant AS, Nelson GW, Chen WD, Ishii H, Chen JM, Hu G, Achyut BR, Yoon EC, Han L, Huang C, Cam MC, et al. Induction of DNMT3B by PGE2 and IL6 at distant metastatic sites promotes epigenetic modification and breast cancer colonization. Cancer Research. PMID 32265226 DOI: 10.1158/0008-5472.Can-19-3339 |
0.468 |
|
| 2018 |
Skrypek N, Bruneel K, Vandewalle C, De Smedt E, Soen B, Loret N, Taminau J, Goossens S, Vandamme N, Berx G. ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transition. Epigenetics & Chromatin. 11: 70. PMID 30445998 DOI: 10.1186/S13072-018-0239-4 |
0.365 |
|
| 2018 |
Drubay V, Skrypek N, Cordiez L, Vasseur R, Schulz C, Boukrout N, Duchêne B, Coppin L, Van Seuningen I, Jonckheere N. TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727. Cancers. 10. PMID 30065235 DOI: 10.3390/Cancers10080254 |
0.769 |
|
| 2017 |
Skrypek N, Goossens S, De Smedt E, Vandamme N, Berx G. Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity. Trends in Genetics : Tig. PMID 28919019 DOI: 10.1016/J.Tig.2017.08.004 |
0.366 |
|
| 2017 |
Bourcy M, Skrypek N, Thompson EW, Berx G, Hollier B, Polette M, Gilles C. Abstract LB-147: EMT transcription factors induce tissue factor expression and pro-coagulant properties, supporting early metastasis of circulating tumor cells Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-147 |
0.351 |
|
| 2017 |
So JY, Skrypek N, Wang X, Merchant A, Yang H, Chen W, Hu G, Achyut BR, Cam M, Zhao K, Lee M, Yang L. Abstract 2843: DNMT3B mediated DNA methylation and epigenetic reprogramming of metastatic cancer cells Cancer Research. 77: 2843-2843. DOI: 10.1158/1538-7445.Am2017-2843 |
0.39 |
|
| 2016 |
Bourcy M, Suarez-Carmona M, Lambert J, Francart ME, Schroeder H, Delierneux C, Skrypek N, Thompson EW, Jerusalem G, Berx G, Thiry M, Blacher S, Hollier BG, Noel A, Oury C, et al. Tissue factor induced by epithelial-mesenchymal transition triggers a pro-coagulant state that drives metastasis of circulating tumor cells. Cancer Research. PMID 27221703 DOI: 10.1158/0008-5472.Can-15-2263 |
0.435 |
|
| 2016 |
Scott CL, Soen B, Martens L, Skrypek N, Saelens W, Taminau J, Blancke G, Van Isterdael G, Huylebroeck D, Haigh J, Saeys Y, Guilliams M, Lambrecht BN, Berx G. The transcription factor Zeb2 regulates development of conventional and plasmacytoid DCs by repressing Id2. The Journal of Experimental Medicine. PMID 27185854 DOI: 10.1084/Jem.20151715 |
0.331 |
|
| 2016 |
Skrypek N, Boukrout N, Lahdaoui F, Schulz C, Vasseur R, Duchêne B, Seuningen IV, Jonckheere N. Abstract B31: The MUC4 oncomucin mediates resistance of human pancreatic cancer cells to FOLFIRINOX drugs Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-B31 |
0.738 |
|
| 2015 |
Vasseur R, Skrypek N, Duchêne B, Renaud F, Martínez-Maqueda D, Vincent A, Porchet N, Van Seuningen I, Jonckheere N. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways. Biochimica Et Biophysica Acta. 1849: 1375-1384. PMID 26477488 DOI: 10.1016/J.Bbagrm.2015.10.014 |
0.746 |
|
| 2015 |
Skrypek N, Vasseur R, Vincent A, Duchêne B, Van Seuningen I, Jonckheere N. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. Oncotarget. 6: 10853-67. PMID 25890497 DOI: 10.18632/Oncotarget.3414 |
0.78 |
|
| 2015 |
Desurmont T, Skrypek N, Duhamel A, Jonckheere N, Millet G, Leteurtre E, Gosset P, Duchene B, Ramdane N, Hebbar M, Van Seuningen I, Pruvot FR, Huet G, Truant S. Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival. Cancer Science. 106: 262-9. PMID 25580640 DOI: 10.1111/Cas.12603 |
0.746 |
|
| 2014 |
Jonckheere N, Skrypek N, Van Seuningen I. Mucins and tumor resistance to chemotherapeutic drugs. Biochimica Et Biophysica Acta. 1846: 142-51. PMID 24785432 DOI: 10.1016/J.Bbcan.2014.04.008 |
0.786 |
|
| 2014 |
Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monte D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis Clinical Cancer Research. 20: 837-846. PMID 24323901 DOI: 10.1158/1078-0432.Ccr-13-1854 |
0.707 |
|
| 2013 |
Jonckheere N, Skrypek N, Frénois F, Van Seuningen I. Membrane-bound mucin modular domains: from structure to function. Biochimie. 95: 1077-86. PMID 23178705 DOI: 10.1016/J.Biochi.2012.11.005 |
0.704 |
|
| 2012 |
Skrypek N, Duchêne B, Hebbar M, Leteurtre E, van Seuningen I, Jonckheere N. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene. 32: 1714-23. PMID 22580602 DOI: 10.1038/Onc.2012.179 |
0.764 |
|
| 2012 |
Jonckheere N, Skrypek N, Merlin J, Dessein AF, Dumont P, Leteurtre E, Harris A, Desseyn JL, Susini C, Frénois F, Van Seuningen I. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. Plos One. 7: e32232. PMID 22393391 DOI: 10.1371/Journal.Pone.0032232 |
0.782 |
|
| 2012 |
Skrypek N, Duchene B, Hebbar M, Leteurtre E, Van Seuningen I, Jonchkeere N. 190 The Mucin MUC4-mediated Chemoresistance of Human Pancreatic Cancer Cells to Gemcitabine and FOLFIRINOX European Journal of Cancer. 48: S46. DOI: 10.1016/S0959-8049(12)70888-2 |
0.55 |
|
| 2010 |
Jonckheere N, Skrypek N, Van Seuningen I. Mucins and pancreatic cancer. Cancers. 2: 1794-812. PMID 24281201 DOI: 10.3390/Cancers2041794 |
0.791 |
|
| 2009 |
Jonckheere N, Skrypek N, Saint-Laurent N, Susini C, VAN SEUNINGEN I. T1998 The Muc4 Membrane-Bound Mucin Alters In Vitro and In Vivo Biological Properties of Human Pancreatic Cancer Cells Gastroenterology. 136: A-617. DOI: 10.1016/S0016-5085(09)62844-4 |
0.718 |
|
| Show low-probability matches. |